ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentPRNewsWire • 11/21/24
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a BetZacks Investment Research • 11/19/24
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsPRNewsWire • 11/19/24
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsBusiness Wire • 11/19/24
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 10/31/24
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025Seeking Alpha • 10/28/24
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/28/24
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaBusiness Wire • 10/24/24
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBioBenzinga • 10/23/24
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung CancerBusiness Wire • 09/09/24
ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'Seeking Alpha • 08/14/24
ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalBusiness Wire • 08/12/24
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerBusiness Wire • 08/06/24